Clinical trials: Chronic Pulmonary Obstruction
Pulmonary Disease, Chronic Obstructive
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II
The primary objective of this study is to assess the long-term efficacy and safety of once daily treatment of BI 1744 CL inhalation solution (5 and 10 mcg) delivered via the Respimat® inhaler, in patients with COPD.
- Trial name
- NCT00796653
- Testing
- Olodaterol (BI 1744), Formoterol
- Where
- 98 sites in Argentina, Brazil and 18 more
- Volunteers
- 937 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease
A study to evaluate the effects of ACT-541468 on respiration in patients with moderate chronic obstructive pulmonary disease
- Trial name
- NCT03646864
- Testing
- ACT-541468
- Where
- 5 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Pulmonary Disease, Chronic Obstructive
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
The prevalence, low cost, and low burden of wearable devices that provide quantitative and qualitative feedback on a subject's activity level present an opportunity for the use of these devices in clinical and observational…
- Trial name
- NCT02619357
- Testing
- SenseWear Armband Gecko, SenseWear Armband MF, Actigraph GT9x wristband and waistband
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease
To monitor the safety profile and effectiveness of Vahelva Respimat in Korean patients with COPD in a routine clinical practice setting
- Trial name
- NCT02864407
- Testing
- Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)
- Where
- South Korea
- Volunteers
- 3,223 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease
To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD
- Trial name
- NCT00465959
- Testing
- trospium chloride inhalation powder (TrIP)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Pulmonary Disease, Chronic Obstructive
A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of GSK233705B.
GSK233705 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for the treatment of chronic obstructive pulmonary disease.
- Trial name
- NCT00453479
- Testing
- GSK233705B
- Where
- 4 sites in Netherlands
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline
Hypogonadism, Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy
The objective of the study is to assess and compare the preliminary efficacy, safety and tolerability of fispemifene 300 mg and placebo given once daily for 4 weeks in the treatment of hypogonadal men with chronic obstructive…
- Trial name
- NCT01061970
- Testing
- Fispemifene
- Volunteers
- 15 people
- Sponsor
- QuatRx Pharmaceuticals Company
Chronic Obstructive Pulmonary Disease, COPD
Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.
The purpose of this study is to investigate the effect of combined treatment with Symbicort and Spiriva, in terms of improvement of lung function, symptoms and inflammatory markers, in patients with severe COPD.
- Trial name
- NCT00496470
- Testing
- Symbicort (budesonide/formoterol turbuhaler 320/9ug), Spiriva (tiotropium bromide 18ug)
- Where
- 93 sites in Australia, Canada and 7 more
- Volunteers
- 660 people
- Sponsor
- AstraZeneca
Cachexia
Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)
Impaired physical function and muscle dysfunction are a major consequence of COPD, which may be associated with increased mortality, poor quality of life and increased health care use.
- Trial name
- NCT03359473
- Testing
- GSK2881078
- Where
- 11 sites in United States, Germany and 1 more
- Volunteers
- 97 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment…
- Trial name
- NCT05878769
- Testing
- Astegolimab
- Where
- 481 sites in United States, Argentina and 38 more
- Volunteers
- 2,000 people
- Sponsor
- Hoffmann-La Roche
Chronic Obstructive Pulmonary Disease
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients
The purpose of this study is to compare a combination asthma drug (Symbicort) with its two components, budesonide and formoterol, taken individually or in combination, and with placebo in the long-term maintenance treatment of…
- Trial name
- NCT00206154
- Testing
- Budesonide/formoterol pMDI, Budesonide pMDI, Formoterol Turbuhaler
- Where
- 212 sites in United States, Czechia and 3 more
- Volunteers
- 1,500 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this trial was to establish non-inferiority of lung function response to tiotropium 10 μg, formulated as inhalation powder in the polyethylene hard capsule and delivered via the HandiHaler® 2, compared to…
- Trial name
- NCT02242266
- Testing
- Tiotropium low dose, Tiotropium medium dose, Spiriva® HandiHaler® high dose
- Volunteers
- 121 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Clinical and Economic Burden of Patients With Chronic Obstructive Pulmonary Disease in a Medicaid Population
Reports suggest that the Medicaid population includes a higher percentage of smokers than the general population. A high prevalence of smokers in a population is likely to lead to a higher burden of chronic obstructive pulmonary…
- Trial name
- NCT01615783
- Testing
- Subjects with COPD, Subjects without COPD
- Volunteers
- 40,884 people
- Sponsor
- GlaxoSmithKline
COPD
Randomized Controlled Eight-Week Study of the Safety and Efficacy of the Lung Flute
This is an eight-week, randomized, controlled, two arm parallel study. The study consists of, a screening visit, two weeks of intervention-free run-in randomization, clinic visits week 0, 1, 2, 4, 6, and 8 weeks during the…
- Trial name
- NCT00560105
- Testing
- Lung Flute, Acapella
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Medical Acoustics LLC
COPD (Chronic Obstructive Pulmonary Disease)
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated…
- Trial name
- THARROS (NCT06283966)
- Testing
- BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg
- Where
- 922 sites in United States, Argentina and 35 more
- Volunteers
- 5,250 people
- Sponsor
- AstraZeneca
Respiratory Disorders
Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstructive Pulmonary Disease and During Acute Exacerbations of the Disease, in Asia Pacific
Since the infectious aetiology of AECOPD has been suggested to vary according to geographical region, the primary purpose of this study (which will be conducted in several countries in Asia Pacific) is to evaluate the occurrence…
- Trial name
- NCT03151395
- Testing
- Sputum and blood sampling
- Where
- 19 sites in Hong Kong, Philippines and 2 more
- Volunteers
- 197 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate the safety and efficacy of the HSK39004 Dry Powder Inhaler compared with the placebo in the treatment of Chinese patients with COPD.
- Trial name
- NCT07108699
- Testing
- HSK39004 Dry Powder Inhaler-0.75mg, HSK39004 Dry Powder Inhaler-1.5mg, HSK39004 Dry Powder Inhaler Simulant
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Pulmonary Disease, Chronic Obstructive
The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD
The purpose of this 24 week study is to evaluate the spirometric lung function effect (trough FEV1) of Umeclidinium/Vilanterol 62.5/25 once daily compared to Tiotropium 18 mcg once daily along with safety assessments in subjects…
- Trial name
- NCT01777334
- Testing
- Umeclidinium/Vilanterol 62.5/25 mcg, Tiotropium 18 mcg
- Where
- 70 sites in United States, Argentina and 7 more
- Volunteers
- 905 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Lung Disease (COLD)
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate the safety and efficacy of the HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension compared with the placebo in the treatment of Chinese patients with COPD.
- Trial name
- NCT07140328
- Testing
- HSK39004 Dry Powder Inhaler -0.75mg BID, HSK39004 Dry Powder Inhaler -1.5mg BID, HSK39004 Inhalation Suspension -3mg BID
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease
Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of the study is to assess the safety and tolerability of multiple infusions of andecaliximab (formerly GS-5745) in participants with chronic obstructive pulmonary disease (COPD) as assessed by adverse events…
- Trial name
- NCT02077465
- Testing
- Andecaliximab
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Gilead Sciences